

Free Trial and Dose Modification Program



CONTACT INFORMATION

Phone: 502-805-3469 | Fax: 502-212-1107 | Email Address: ZejulaDE@pharmacord.com

ENROLLMENT FORM

The ZEJULA Free Trial and Dose Modification Program is available for new patients or patients who require mid-cycle dose changes of their current tablet strength. A 30-count bottle of ZEJULA will be provided to your patient at no cost.

INSTRUCTIONS FOR PRESCRIBER



Complete

Review and complete this entire form



Sign

Prescriber must sign and date at the bottom of **section 4**



Fax

Fax this entire form to: 502-212-1107

ELIGIBILITY REQUIREMENTS

To be eligible for the ZEJULA Free Trial and Dose Modification Program, a patient must:

- Be a legal resident of the United States (including Washington DC, Puerto Rico, US Virgin Islands, or US territories)
- Be prescribed ZEJULA for a US Food and Drug Administration (FDA)-approved indication
- Have remaining pills, from a current prescription for an FDA-approved indication, for those changing doses
- If using the first time, must not have already received a dose from the Free Trial Program
- Not have already had 2 separate dose adjustments from the Dose Modification Program if changing doses
- Not be receiving ZEJULA from the Patient Assistance Program

The program is available to all patients who meet eligibility requirements, including those enrolled in Medicare or other government-funded programs.

Please note: To provide your patient a new dose of ZEJULA at no charge, this program is dispensed by PharmaCord Pharmacy rather than your in-office dispensary or the specialty pharmacy that is currently dispensing your patient's prescription. ZEJULA can be shipped to the patient as early as 24 hours after the receipt of this form, if the completed form is received before 3 PM ET.

For ongoing refills, a new prescription will need to be submitted to the patient's existing specialty or in-office dispensing pharmacy. We will contact your office after your patient's dose has been shipped so that you may adjust the next month's prescription as needed.

Future prescriptions are not required to participate in the ZEJULA Free Trial and Dose Modification Program.

SECTION 1. PATIENT INFORMATION

Name: _____ DOB (mm/dd/yyyy): _____ Phone: _____

Address: _____

Email: _____ Best time to contact: _____

Alternative Contact Name: _____ Phone: _____

SECTION 2. PRESCRIBER INFORMATION

Name: _____ Practice: _____

Address: _____

Office Contact: _____ Preferred method of contact: Phone Fax Email

Phone: _____ Fax: _____ Email: _____

NPI#: _____ State License #: _____ Tax ID#: _____ DEA#: _____

Free Trial and Dose Modification Program



Patient Name: _____ Patient DOB: MM / DD / YYYY

SECTION 3. PRESCRIPTION INFORMATION

Provider Name: _____ Provider NPI: _____ Provider Phone: _____

FREE TRIAL PROGRAM

New Prescription (Select only 1)

- ZEJULA 200-mg tablets PO QD #30
- ZEJULA 300-mg tablets PO QD #30



DOSE MODIFICATION PROGRAM

Current Prescription Dose (Select only 1)

- ZEJULA 100-mg tablets PO QD #30
- ZEJULA 200-mg tablets PO QD #30
- ZEJULA 300-mg tablets PO QD #30

New Prescription Dose (Select only 1)

- ZEJULA 100-mg tablets PO QD #30
- ZEJULA 200-mg tablets PO QD #30
- ZEJULA 300-mg tablets PO QD #30

Diagnosis Code: _____

“Dispense As Written” / Brand Medically Necessary /
Do Not Substitute / No Substitution / DAW / May Not Substitute

Prescriber’s Signature: _____ SIGNATURE HERE

Date: MM / DD / YYYY

May Substitute / Product Selection Permitted /
Substitution Permissible

Prescriber’s Signature: _____ SIGNATURE HERE

Date: MM / DD / YYYY

Special Note: If a New York prescriber, please use an original New York State prescription form. The prescriber is to comply with the prescriber’s state-specific prescription requirements.

Known Drug Allergies: _____

Current Medications: _____

Please Note: For ongoing refills, a new prescription will need to be submitted to the patient’s existing specialty or in-office dispensing pharmacy. Future prescriptions are not required to participate in the ZEJULA Free Trial and Dose Modification Program.

SECTION 4. TERMS AND CONDITIONS

- The ZEJULA Free Trial and Dose Modification Program is available at no charge to any patient prescribed ZEJULA for an FDA-approved indication.
- Patients using ZEJULA for the first time must not have already received a dose from the Free Trial Program.
- Patients who are changing doses must not have already had two (2) separate dose adjustments under the Dose Modification Program.
- No one participating in the program may bill or seek payment or reimbursement for tablets received from the program from any third-party payer, including any state or federal entity or any private or other insurance plan.
- Those prohibited from billing or seeking payment or reimbursement for tablets received from the program include patients, prescribers, institutions, pharmacies, pharmacists, or any other person or prescriber.
- Medicare Part D patients who participate in the Program must agree that no part of the costs of the drug provided as part of the Program shall be counted towards their out-of-pocket costs, and no claim will be filed with a Part D plan for drug supplied by the Program.
- Product provided pursuant to this Free Trial Program and Dose Modification Program may not be sold, traded, or distributed for sale.
- GSK reserves the right to change or end the program at any time without notice.

Prescriber: I certify that I understand and agree: 1) That I have explained to my patient the Terms and Conditions of the ZEJULA Trial Program; 2) I am licensed to prescribe the prescription medication identified in this form; (3) the prescription complies with my state-specific prescribing requirements; 4) In my medical judgment, the starting or the new strength of ZEJULA is clinically appropriate for the patient named above and its use is consistent with the FDA-approved indication; and 5) This supply of ZEJULA is specifically for the patient named above.

PRESCRIBER’S SIGNATURE _____

NO STAMPS PLEASE

Date: MM / DD / YYYY

Trademarks are owned by or licensed to the GSK group of companies.



©2023 GSK or licensor
NRPBROC230017 June 2023
Produced in USA. 0002-0025-59